Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02653196 · ClinicalTrials.gov registry record · Early Phase 1
A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors
A Early Phase 1 study, sponsored by Montefiore Medical Center.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 1
- Enrollment target
NCT02653196 is a Early Phase 1 study that was terminated before completion, run by Montefiore Medical Center. The registered enrollment target is 1 participants.
The verdict
NCT02653196, a Early Phase 1 study, was terminated before completion, sponsored by Montefiore Medical Center.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
There is currently no standard treatment for patients with neuro-epithelial (brain) or other solid tumors in another part of the body who do not have adequate suitable autologous hematopoietic progenitor cells available and/or whose disease has relapsed after standard treatment. Allogeneic Hematopoietic Progenitor Cell Transplant may be a consideration for treatment of patients with recurrent chemo-responsive malignant (high grade) neuro-epithelial and other solid tumors or those who do not have suitable autologous hematopoietic progenitor cell availability. The procedure in which your own blood stem cells are transplanted to you is called an autologous (from your own) progenitor cell transplant and when cells from a matched donor are transfused is called an allogeneic progenitor cell transplant. The study is being conducted to evaluate the safety and effectiveness of a combination of drugs followed by an allogeneic hematopoietic progenitor cell transplant (HPCT). This treatment regimen is experimental in that although the individual drugs are commonly used to treat your disease, the specific combination used in this protocol followed by the transplant is experimental.
Interventions
- DRUG Alemtuzumab
- DRUG Etoposide
- DRUG Thiotepa
- PROCEDURE Allogeneic hematopoietic stem cell transplant following thiotepa-based marrow ablative chemotherapy
- DRUG Keratinocyte Growth Factor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2015-09 |
| Est. Completion | 2017-08 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02653196
The ClinicalTrials.gov registry entry for NCT02653196 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Alemtuzumab is the first listed.
NCT02653196 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02653196 about?
NCT02653196 is a clinical study titled "A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors". There is currently no standard treatment for patients with neuro-epithelial (brain) or other solid tumors in another part of the body who do not have adequate suitable autologous hematopoietic progenitor cells available and/or whose disease has relapsed after standard treatment. Allogeneic Hematopoi...
What is the current status of trial NCT02653196?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 1 participants. The study started on 2015-09. Estimated completion is 2017-08.
What interventions are being tested in trial NCT02653196?
The interventions under investigation include: Alemtuzumab (DRUG), Etoposide (DRUG), Thiotepa (DRUG), Allogeneic hematopoietic stem cell transplant following thiotepa-based marrow ablative chemotherapy (PROCEDURE), Keratinocyte Growth Factor (DRUG).
Who is sponsoring clinical trial NCT02653196?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.